| New Corneal Implant Tested in Indianapolis
The Indianapolis-based Cornea Research Foundation of America is one of 35 sites nationwide that is participating in a clinical study on a new implant to prevent corneal transplant rejection. The new silicone implant steadily releases small amounts of a drug commonly used to prevent the rejection of kidney and other solid organ transplants. Typically, the drugs are administered after the surgery, but experts say up to a third of corneal transplants fail. Dr. Francis Price, Jr., owner of Price Vision Group in Indianapolis, became the first physician in the world last week to perform the procedure.
Source: Inside INdiana Business
.
Ziemer to take over marketing of Amadeus II microkeratome from AMO
Ziemer Group announced that it will assume all worldwide marketing, sales and support duties for the Amadeus II automated microkeratome from Advanced Medical Optics. The Amadeus product line, although originally created by a Ziemer subsidiary, has been sold by AMO since its launch in 1999, according to a press release from Ziemer. Ziemer has developed a global marketing and distribution network during the last 8 years while AMO has been marketing the Amadeus products. Ziemer will now rely on that network, said Frank Ziemer, Ziemer CEO, in the release. "We can assure AMO's customers that we will provide a seamless transition and will do our utmost to be a competent and responsive partner," he said. The Amadeus II builds on the original Amadeus and features enhanced handling and optional accessories for epi-LASIK and lamellar keratoplasty, the release said.
Inspired event
The BCLA expects top international speakers to draw record numbers to its clinical conference and exhibition from May 31-June 3. Around 675 delegates have so far registered for the conference in Manchester. The scientific programme offers a total of 33 CET points, 27 of which are contact lens specific. The worldwide myopia epidemic will be covered in a full-day symposium. Microbial keratitis, dry eye, corneal staining and the future of contact lens practice are also topics for discussion. An Alcon-sponsored welcome lecture on the evening of May 31 with a speech by Professor Lyndon Jones will be followed by a presentation by Alcon on its latest solution. Bausch & Lomb will launch its latest daily disposable lens and Johnson & Johnson Vision Care will host its 'Be the best you can be' event with an 'inspirational talk' by Sir Clive Woodward.
Canada's New Government announces Patient Wait Times Guarantees
Health is a unity and harmony within the mind, body and spirit which is unique to each person, and is as defined by that person. The level of wellness or health is, in part, determined by the ability to deal with and defend against stress. Health is determined by physiological, psychological, socio-cultural, spiritual, and developmental stage variables. .
Positive Results Prompt US National Cancer Institute To Make ...
Investigators will begin offering Gleevec(R) (imatinib mesylate) tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.
The interim analysis showed no recurrence of cancer in approximately 97% of patients given Gleevec for a year after surgery to remove tumors, compared to approximately 83% of those who underwent surgery but received a placebo. The investigators made these results public because the study had met its primary endpoint in terms of rate of recurrence-free survival.
The study involving more than 600 patients was sponsored by the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH).
|
